
Opinion|Videos|February 14, 2025
Ensifentrine (ENHANCE Trials) in COPD
Panelists discuss how the ENHANCE trials assessed ensifentrine in patients with chronic obstructive pulmonary disease (COPD) with moderate-to-severe airflow obstruction and a history of exacerbations. Outcomes showed improved lung function and reduced exacerbations. Clinically, ensifentrine may be used as monotherapy or an add-on, addressing diverse patient needs.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Ensifentrine is recommended in the 2025 GOLD Report as a bronchodilator to improve dyspnea. Ensifentrine is also suggested as a potential anti-inflammatory therapy in stable COPD.
- What were the main patient eligibility criteria and clinical outcomes in the ENHANCE trials?
- How do you anticipate that ensifentrine will be used in clinical practice (ie, monotherapy, add-on, both)?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Interstitial Lung Abnormalities: Recognition, Risk Stratification, and When to Act
2
Management Strategies for Hypercortisolism
3
Q&A: Intensive LDL Lowering and Cardiovascular Prevention Strategies, With Lawrence Leiter, MD
4
Long-Term Treatment Adherence and Persistence in Hypercortisolism
5

























































































